RECURRENT ENDOMETRIAL CANCER
Clinical trials for RECURRENT ENDOMETRIAL CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL CANCER trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug duo aims to stall recurrent uterine cancer
Disease control Recruiting nowThis study tests whether two drugs, abemaciclib and letrozole, can help keep advanced or recurrent endometrial cancer from progressing. The trial enrolls 32 people with a specific type of cancer (ER-positive, mismatch repair proficient, TP53 wildtype). Participants take the drugs…
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 17, 2026 00:53 UTC
-
New antibody combo shows promise for Tough-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests an experimental drug called ubamatamab, given alone or with another drug (cemiplimab), for people with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back. The main goals are to check safety, find the best dose, and see if the drugs can …
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:51 UTC